PALO ALTO, Calif., Aug. 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR ), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at two upcoming meetings in September in New York City.